FI970867A - Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin systeemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamiseksi - Google Patents

Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin systeemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamiseksi Download PDF

Info

Publication number
FI970867A
FI970867A FI970867A FI970867A FI970867A FI 970867 A FI970867 A FI 970867A FI 970867 A FI970867 A FI 970867A FI 970867 A FI970867 A FI 970867A FI 970867 A FI970867 A FI 970867A
Authority
FI
Finland
Prior art keywords
processes
preparation
controlled release
dosing systems
solid dosing
Prior art date
Application number
FI970867A
Other languages
English (en)
Swedish (sv)
Other versions
FI970867A0 (fi
Inventor
Bruce Joseph Roser
Camilo Colaco
Mohamed Abdel Zahra Jerrow
Julian Alexander Landcli Blair
Jaap Kampinga
James Lewis Wardell
John Alistair Duffy
Original Assignee
Quadrant Holdings Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI970867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9415810A external-priority patent/GB9415810D0/en
Priority claimed from US08/349,029 external-priority patent/US6290991B1/en
Application filed by Quadrant Holdings Cambridge filed Critical Quadrant Holdings Cambridge
Publication of FI970867A0 publication Critical patent/FI970867A0/fi
Publication of FI970867A publication Critical patent/FI970867A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Lubricants (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI970867A 1994-08-04 1997-02-28 Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin systeemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamiseksi FI970867A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415810A GB9415810D0 (en) 1994-08-04 1994-08-04 Composition
US08/349,029 US6290991B1 (en) 1994-12-02 1994-12-02 Solid dose delivery vehicle and methods of making same
PCT/GB1995/001861 WO1996003978A1 (en) 1994-08-04 1995-08-04 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Publications (2)

Publication Number Publication Date
FI970867A0 FI970867A0 (fi) 1997-02-28
FI970867A true FI970867A (fi) 1997-04-08

Family

ID=26305403

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970867A FI970867A (fi) 1994-08-04 1997-02-28 Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin systeemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamiseksi

Country Status (20)

Country Link
EP (4) EP0773781B1 (fi)
JP (2) JPH10503769A (fi)
CN (1) CN1152670C (fi)
AT (1) ATE252373T1 (fi)
BG (1) BG101278A (fi)
CA (1) CA2197982C (fi)
CZ (1) CZ297431B6 (fi)
DE (1) DE69531992T2 (fi)
DK (1) DK0773781T3 (fi)
EE (1) EE03593B1 (fi)
ES (1) ES2208687T3 (fi)
FI (1) FI970867A (fi)
HU (1) HUT77777A (fi)
MX (1) MX9701394A (fi)
NO (1) NO326966B1 (fi)
NZ (1) NZ290896A (fi)
PL (1) PL184068B1 (fi)
PT (1) PT773781E (fi)
SK (1) SK283026B6 (fi)
WO (1) WO1996003978A1 (fi)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU3570495A (en) 1994-09-22 1996-04-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
AU8229998A (en) * 1997-07-03 1999-01-25 Quadrant Holdings Cambridge Limited Modified glycosides, compositions comprised thereof and methods of use thereof
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US6187330B1 (en) * 1998-01-30 2001-02-13 Scios Inc. Controlled release delivery of peptide or protein
US6455096B1 (en) 1998-04-28 2002-09-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Hard candy with a relatively-high moisture and hardness, and process of the same
AU5751799A (en) * 1998-09-09 2000-03-27 Quadrant Holdings Cambridge Limited Filamentous amorphous carbohydrate compositions and therapeutic delivery vehicles comprising them
ATE244558T1 (de) 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
JP3419729B2 (ja) * 2000-03-16 2003-06-23 株式会社ファンケル 錠剤およびその製造方法
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
EP1449523A1 (en) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Composition and method for stable injectable liquids
HUP0302924A2 (en) 2000-10-26 2003-12-29 Alza Corp Transdermal drug delivery devices having coated microprotrusions
CN100349632C (zh) * 2001-04-20 2007-11-21 阿尔扎公司 具有包含有益药剂的涂层的微小突出物阵列
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
DE10157124A1 (de) * 2001-11-21 2003-05-28 Lohmann Therapie Syst Lts Mikrofaserhaltige Vorrichtung zur kontrollierten Freisetzung von Stoffen
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
JP2005519905A (ja) * 2002-01-25 2005-07-07 グラクソ　グループ　リミテッド Ｄｎａの製剤
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0210771D0 (en) * 2002-05-10 2002-06-19 Univ London Pharmacy Derivatised particulate inhalation carriers
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
EP1638523B8 (en) 2003-06-30 2013-12-25 ALZA Corporation Formulations for coated microprojections containing non-volatile counterions
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
PT1765294E (pt) 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
JP4547994B2 (ja) * 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20090155351A1 (en) 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
US8632801B2 (en) 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US7862540B2 (en) 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US20070270750A1 (en) 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US7815603B2 (en) 2006-05-17 2010-10-19 Alcon Research, Ltd. Ophthalmic injection method
US7811252B2 (en) 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US7887521B2 (en) 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US7674243B2 (en) 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US20080281292A1 (en) 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
CA2669913C (en) * 2006-11-21 2012-09-18 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
US7740619B2 (en) 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
US7629768B2 (en) 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
WO2011137420A1 (en) * 2010-04-30 2011-11-03 Apellis Pharmaceuticals, Inc. Methods, articles and kits for allergic desensitization via the oral mucosa
EP2397484A1 (en) * 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharide derivates, and their use as adjuvants
IN2014CN03555A (fi) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
KR101574760B1 (ko) 2013-11-13 2015-12-04 주식회사 엘지생활건강 흡수속도를 개선한 마이크로니들 시스템
JP6556632B2 (ja) 2013-12-16 2019-08-07 武田薬品工業株式会社 マイクロニードル
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
KR102587444B1 (ko) 2015-09-29 2023-10-11 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승 조성물
KR102114993B1 (ko) * 2015-10-15 2020-05-25 주식회사 파이안에스테틱스 폴리펩타이드 및/또는 세포 배양 여액을 함유하는 수용성 스크럽 입자를 포함하는 화장제 조성물
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
US10751408B2 (en) * 2016-02-23 2020-08-25 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
KR20190120235A (ko) 2017-02-28 2019-10-23 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
WO2023077447A1 (zh) * 2021-11-05 2023-05-11 中国科学院过程工程研究所 环肽玻璃及含有环肽的药物组合物玻璃

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1080265B (de) * 1958-09-30 1960-04-21 Bayer Ag Verfahren zur Herstellung von oral anzuwendenden Arzneimittel-zubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4891319A (en) 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01288023A (ja) * 1988-05-16 1989-11-20 Nec Corp ミリ波構内無線通信方式
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1990011756A1 (en) 1989-04-12 1990-10-18 Aberdeen University Slow release vitreous systems
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009390D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Pharmaceutical compositions
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
DK42093D0 (da) * 1993-04-07 1993-04-07 Bukh Meditec Administrationsmetode
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe

Also Published As

Publication number Publication date
AU3185195A (en) 1996-03-04
FI970867A0 (fi) 1997-02-28
EP1138319A2 (en) 2001-10-04
JP2006056898A (ja) 2006-03-02
HUT77777A (hu) 1998-08-28
EP1516615A3 (en) 2007-10-31
EP1138337A3 (en) 2003-03-26
PL184068B1 (pl) 2002-08-30
ATE252373T1 (de) 2003-11-15
JPH10503769A (ja) 1998-04-07
PT773781E (pt) 2004-03-31
EP0773781A1 (en) 1997-05-21
DE69531992D1 (de) 2003-11-27
EE9700062A (et) 1997-08-15
BG101278A (en) 1997-12-30
DK0773781T3 (da) 2004-02-16
CA2197982C (en) 2010-03-23
CZ297431B6 (cs) 2006-12-13
MX9701394A (es) 1998-03-31
AU688557B2 (en) 1998-03-12
NO971688D0 (no) 1997-04-11
CZ47697A3 (en) 1997-08-13
ES2208687T3 (es) 2004-06-16
EP1138319A3 (en) 2003-03-19
CN1204959A (zh) 1999-01-13
DE69531992T2 (de) 2004-07-22
CN1152670C (zh) 2004-06-09
NO326966B1 (no) 2009-03-23
EP0773781B1 (en) 2003-10-22
SK283026B6 (sk) 2003-02-04
PL318898A1 (en) 1997-07-21
SK27797A3 (en) 1997-08-06
EP1516615A2 (en) 2005-03-23
WO1996003978A1 (en) 1996-02-15
NO971688L (no) 1997-04-11
CA2197982A1 (en) 1996-02-15
EP1138337A2 (en) 2001-10-04
EE03593B1 (et) 2002-02-15
NZ290896A (en) 1997-04-24

Similar Documents

Publication Publication Date Title
FI970867A (fi) Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin systeemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamiseksi
DE69812711D1 (de) Kohlenhydraten verwendbar in feste verabreichungssysteme
Crich et al. Influence of the 4, 6-O-benzylidene, 4, 6-O-phenylboronate, and 4, 6-O-polystyrylboronate protecting groups on the stereochemical outcome of thioglycoside-based glycosylations mediated by 1-benzenesulfinyl piperidine/triflic anhydride and N-iodosuccinimide/trimethylsilyl triflate
SE8503486D0 (sv) Tverbundna geler av hyaluronsyra, metod for framstellning av sadana geler och produkter som innehaller sadana geler
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
ES2122041T3 (es) Glicosidos triantenarios aglomerados, su preparacion y utilizacion.
MY110560A (en) Additives to feminine hygene products
AU647484B2 (en) Composition and method for topical treatment of damaged or diseased tissue
BR1100612A (pt) Biconjugado apropriado contituìdo de dois sacarìdeos e um espaçador, seu uso e composição farmacêutica
PT994887E (pt) Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
RU2007114366A (ru) Перевязочный материал для ухода за раной и способ его использования
Plante et al. Formation of β-glucosamine and β-mannose linkages using glycosyl phosphates
BR9104502A (pt) Derivados de galactomanano para o envolvimento ou embutidura de substancias ativas de medicamentos
WO1995035112A3 (en) Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof
WO2002036600A3 (en) Derivatised carbohydrates and their use in solid delivery systems
SE7900738L (sv) Farmaceutiskt medel
ATE204287T1 (de) Neue o-sulfatierte ganglioside und lyso- ganglioside-derivaten
Portoukalian The inhibitory effect of tumor-shed gangliosides on the production of IL-1beta by monocytes as well as on the proliferative activity of this lymphokine on thymocytes depends on the structures of both oligosaccharide and ceramide moieties of the gangliosides
KR960000212A (ko) 친수성 고분자 물질을 함유하는 소수성 고분자 매트릭스를 이용한 경구용 약물 전달 체계
El Said < The> use of honey in dressing of septic wounds versus cetrimide 15+ chlorhexidine gluconate 15 [savlon]: randomized, controlled clinical trial
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni

Legal Events

Date Code Title Description
NF Re-establishment of lapsed right
PC Transfer of assignment of patent

Owner name: QUADRANT DRUG DELIVERY LIMITED

Free format text: QUADRANT DRUG DELIVERY LIMITED